Inmed pharmaceuticals reports full year fiscal 2022 financial results and provides business update

Vancouver, british columbia, sept. 23, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended june 30, 2022.
INM Ratings Summary
INM Quant Ranking